However, in terms of OS, the median OS time for patients treated with celecoxib plus chemotherapy was only 9 months, indicating that some patients benefited from this combination treatment, especially patients selected based on COX-2 expression in the tumor, because celecoxib inhibited the COX-2 and PGE2 levels induced by chemotherapy in tumors. The gene discussed is PTGS2; the disease is neoplasm.